DB-1310 by Duality Biologics (Shanghai) for Solid Tumor: Likelihood of Approval

The new changes will make it easier for clinical trials patients to receive payment. Image credit: PopTika via Shutterstock. Skyelarke, the health technology company specialising

Less than a year in­to a rocky roll­out for its gene ther­a­py Roc­ta­vian, Bio­Marin is now talk­ing about whether the prod­uct might be a bet­ter